Eyepoint Pharmaceuticals Stock Buy Hold or Sell Recommendation
| EYPT Stock | USD 6.52 0.31 4.54% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Eyepoint Pharmaceuticals is 'Strong Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Eyepoint Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Eyepoint Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Eyepoint Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as Eyepoint and provide practical buy, sell, or hold advice based on investors' constraints. Eyepoint Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Eyepoint |
Execute Eyepoint Pharmaceuticals Buy or Sell Advice
The Eyepoint recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Eyepoint Pharmaceuticals. Macroaxis does not own or have any residual interests in Eyepoint Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Eyepoint Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Eyepoint Pharmaceuticals Trading Alerts and Improvement Suggestions
| Eyepoint Pharmaceuticals generated a negative expected return over the last 90 days | |
| Eyepoint Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 43.27 M. Net Loss for the year was (130.87 M) with profit before overhead, payroll, taxes, and interest of 21.09 M. | |
| Eyepoint Pharmaceuticals currently holds about 171.17 M in cash with (126.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.02. | |
| Eyepoint Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Acquisition by Zaderej Karen L. of 40000 shares of Eyepoint Pharmaceuticals at 8.26 subject to Rule 16b-3 |
Eyepoint Pharmaceuticals Returns Distribution Density
The distribution of Eyepoint Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Eyepoint Pharmaceuticals' future price movements. The chart of the probability distribution of Eyepoint Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Eyepoint Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Eyepoint Pharmaceuticals returns is essential to provide solid investment advice for Eyepoint Pharmaceuticals.
| Mean Return | -0.14 | Value At Risk | -7.23 | Potential Upside | 6.81 | Standard Deviation | 5.10 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Eyepoint Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Eyepoint Stock Institutional Investors
The Eyepoint Pharmaceuticals' institutional investors refer to entities that pool money to purchase Eyepoint Pharmaceuticals' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Goldman Sachs Group Inc | 2024-12-31 | 1.7 M | Geode Capital Management, Llc | 2024-12-31 | 1.5 M | Perceptive Advisors Llc | 2024-03-31 | 1.5 M | State Street Corp | 2024-12-31 | 1.5 M | Patient Square Capital | 2024-12-31 | 1.4 M | Essex Woodlands Health Ventures | 2024-12-31 | 1.2 M | Finepoint Capital Lp | 2024-12-31 | 1.1 M | 5am Venture Management, Llc | 2024-12-31 | 1.1 M | Point72 Asset Management, L.p. | 2024-12-31 | 857.9 K | Cormorant Asset Management, Llc | 2024-12-31 | 8.3 M | Suvretta Capital Management, Llc | 2024-12-31 | 6.8 M |
Eyepoint Pharmaceuticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 22.7M | 133.7M | (83.0M) | 185.6M | (181.6M) | (172.5M) | |
| Free Cash Flow | (14.8M) | (50.3M) | (67.2M) | (1.6M) | (130.3M) | (123.8M) | |
| Depreciation | 2.6M | 2.8M | 2.4M | 464K | 1.5M | 1.8M | |
| Other Non Cash Items | 1.7M | 628K | 23.6M | 1.2M | (6.0M) | (5.7M) | |
| Capital Expenditures | 362K | 156K | 2.2M | 3.5M | 4.1M | 4.3M | |
| Net Income | (45.4M) | (58.4M) | (102.3M) | (70.8M) | (130.9M) | (124.3M) | |
| End Period Cash Flow | 45.1M | 178.7M | 95.8M | 281.3M | 99.9M | 104.8M | |
| Change To Inventory | (3.2M) | 1.3M | (760K) | (1.6M) | 1.6M | 1.7M | |
| Change To Netincome | 9.4M | 7.4M | 6.7M | 38.4M | 44.1M | 46.3M | |
| Net Borrowings | 25.9M | (14.6M) | (146K) | (653K) | (587.7K) | (558.3K) |
Eyepoint Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Eyepoint Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Eyepoint Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Eyepoint stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.02 | |
β | Beta against Dow Jones | 0.91 | |
σ | Overall volatility | 5.18 | |
Ir | Information ratio | -0.0015 |
Eyepoint Pharmaceuticals Volatility Alert
Eyepoint Pharmaceuticals exhibits very low volatility with skewness of -0.07 and kurtosis of 0.47. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Eyepoint Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Eyepoint Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Eyepoint Pharmaceuticals Fundamentals Vs Peers
Comparing Eyepoint Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Eyepoint Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Eyepoint Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Eyepoint Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Eyepoint Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Eyepoint Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Eyepoint Pharmaceuticals to competition |
| Fundamentals | Eyepoint Pharmaceuticals | Peer Average |
| Return On Equity | -0.43 | -0.31 |
| Return On Asset | -0.24 | -0.14 |
| Operating Margin | (3.90) % | (5.51) % |
| Current Valuation | 154.73 M | 16.62 B |
| Shares Outstanding | 68.73 M | 571.82 M |
| Shares Owned By Insiders | 1.13 % | 10.09 % |
| Shares Owned By Institutions | 98.87 % | 39.21 % |
| Number Of Shares Shorted | 11.09 M | 4.71 M |
| Price To Earning | (2.82) X | 28.72 X |
| Price To Book | 1.50 X | 9.51 X |
| Price To Sales | 10.85 X | 11.42 X |
| Revenue | 43.27 M | 9.43 B |
| Gross Profit | 21.09 M | 27.38 B |
| EBITDA | (129.23 M) | 3.9 B |
| Net Income | (130.87 M) | 570.98 M |
| Cash And Equivalents | 171.17 M | 2.7 B |
| Cash Per Share | 5.02 X | 5.01 X |
| Total Debt | 21.86 M | 5.32 B |
| Debt To Equity | 0.30 % | 48.70 % |
| Current Ratio | 6.16 X | 2.16 X |
| Book Value Per Share | 4.93 X | 1.93 K |
| Cash Flow From Operations | (126.23 M) | 971.22 M |
| Short Ratio | 11.92 X | 4.00 X |
| Earnings Per Share | (2.32) X | 3.12 X |
| Target Price | 33.0 | |
| Number Of Employees | 165 | 18.84 K |
| Beta | 1.42 | -0.15 |
| Market Capitalization | 469.42 M | 19.03 B |
| Total Asset | 418.46 M | 29.47 B |
| Retained Earnings | (873.02 M) | 9.33 B |
| Working Capital | 334.26 M | 1.48 B |
| Current Asset | 15.08 M | 9.34 B |
| Current Liabilities | 11.26 M | 7.9 B |
Note: Disposition of 7000 shares by Duker Jay S. of Eyepoint Pharmaceuticals subject to Rule 16b-3 [view details]
Eyepoint Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Eyepoint . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 86346.59 | |||
| Daily Balance Of Power | (0.50) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 6.75 | |||
| Day Typical Price | 6.67 | |||
| Price Action Indicator | (0.39) | |||
| Period Momentum Indicator | (0.31) |
About Eyepoint Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Eyepoint Pharmaceuticals? Buying financial instruments such as Eyepoint Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Eyepoint Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Warren Buffett Holdings Thematic Idea Now
Warren Buffett Holdings
A long-term portfolio of publicly-traded stocks on US exchanges that are owned by Warren Buffett's holding company Berkshire Hathaway. The Warren Buffett Holdings theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Warren Buffett Holdings Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.